Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Favezelimab/Pembrolizumab · MK-4280A

Monoclonal antibody · Immune activation, directed at LAG3 and PD-1 (PDCD1) · developed by Merck &

Phase 3 Most advanced trial
MRK Developer

What is Favezelimab/Pembrolizumab?

Favezelimab/pembrolizumab is a coformulation of two humanized IgG4 monoclonal antibodies: favezelimab, which binds LAG3 on tumor-infiltrating lymphocytes and blocks its interaction with MHC class II, and pembrolizumab, which binds PD-1 and blocks its activation by PD-L1 and PD-L2. It is studied in solid tumors and hematologic malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MK-4280A
Drug type
Monoclonal antibody
Targets
LAG3, PD-1 (PDCD1)
Mechanism
Immune activation, directed at LAG3 and PD-1 (PDCD1)
Pathways
T-cell activation, MHC class II interaction blockade, PD-1/PD-L1 signaling blockade
Therapy area
Oncology
Developer
Merck & Co. (MRK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

Conditions studied

Hematologic MalignanciesSolid Tumors

Other drugs acting on LAG3 / PDCD1

More from Merck &

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Favezelimab/Pembrolizumab

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.